An assessment of antiviral drugs for the management of infectious diseases in humans
Identifieur interne : 001402 ( Istex/Corpus ); précédent : 001401; suivant : 001403An assessment of antiviral drugs for the management of infectious diseases in humans
Auteurs : George J. GalassoSource :
- Antiviral Research [ 0166-3542 ] ; 1981.
English descriptors
- Teeft :
- Abrupt onset, Adenine, Adenine arabinoside, Adenine arabinoside monophosphate, Adenine arabinoslde, Adenine arabinoslde monophosphate, Adenine arabmoside, Adenine arabmoslde, Adenine arabmoslde monophosphate, Amantadine, Antiviral, Antiviral agent, Antiviral agents, Antiviral drugs, Antivlral, Antivlral agents, Antlvlral agents, Arabinoside, Arabinoslde, Arabmoslde, Ascorbic acid, Beneficial effects, Beneficial role, Best results, Biomedical press, Brain tissue, Carrier rate, Chmcal study, Chnical, Clinical efficacy, Clinical studies, Collaborative study, Conclusive evidence, Core antigen, Corneal ulceration, Cytosine arabinoslde, Dane particles, Definitive study, Dos, Dosage, Drug therapy, Early promise, Echo viruses, Efficacy, Encephalitis, Etiological agent, Exciting results, Exogenous interferon, Genital herpes, Government authorities, Hepatitis, Herpes, Herpes encephalitis, Herpes genitalis, Herpes labialis, Herpes simplex, Herpes simplex virus, Herpes simplex virus type, Herpes viruses, Herpes zoster, High risk, Historic controls, Infection, Influenza, Influenza epidemics, Influenza pneumonia, Influenza viruses, Interferon, Lassa fever, Liver biopsy, Major problem, Monophosphate, Mortahty rate, Mortality rate, Neonatal herpes, Ocular herpes, Ointment, Older patients, Open studies, Ophthalmic ointment, Ophthalmic solution, Other agents, Other drugs, Other studies, Partial reduction, Personal communication, Petrolatum base, Placebo, Placebo group, Placebo groups, Pregnant women, Primary refection, Prophylaxis, Rapid clearance, Raven press, Recurrence, Recurrence rate, Refection, Renal function, Respiratory disease, Rhinovirus, Rhinovirus infections, Rhinovirus type, Rimantadine, Several agents, Shortest time, Side effects, Simplex, Such agents, Surface antigen, Therapeutic effect, Therapeutic efficacy, Topical treatment, Toxic level, Toxicity, Vaccine, Viral, Viral diseases, Viral infections, Virus, Zoster.
Url:
DOI: 10.1016/0166-3542(81)90035-8
Links to Exploration step
ISTEX:5B16ABB788D66804F28AADB9F02251C61DB44691Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>An assessment of antiviral drugs for the management of infectious diseases in humans</title><author><name sortKey="Galasso, George J" sort="Galasso, George J" uniqKey="Galasso G" first="George J." last="Galasso">George J. Galasso</name><affiliation><mods:affiliation>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5B16ABB788D66804F28AADB9F02251C61DB44691</idno><date when="1980" year="1980">1980</date><idno type="doi">10.1016/0166-3542(81)90035-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001402</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001402</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">An assessment of antiviral drugs for the management of infectious diseases in humans</title><author><name sortKey="Galasso, George J" sort="Galasso, George J" uniqKey="Galasso G" first="George J." last="Galasso">George J. Galasso</name><affiliation><mods:affiliation>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Antiviral Research</title><title level="j" type="abbrev">AVR</title><idno type="ISSN">0166-3542</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1981">1981</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="73">73</biblScope><biblScope unit="page" to="96">96</biblScope></imprint><idno type="ISSN">0166-3542</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abrupt onset</term><term>Adenine</term><term>Adenine arabinoside</term><term>Adenine arabinoside monophosphate</term><term>Adenine arabinoslde</term><term>Adenine arabinoslde monophosphate</term><term>Adenine arabmoside</term><term>Adenine arabmoslde</term><term>Adenine arabmoslde monophosphate</term><term>Amantadine</term><term>Antiviral</term><term>Antiviral agent</term><term>Antiviral agents</term><term>Antiviral drugs</term><term>Antivlral</term><term>Antivlral agents</term><term>Antlvlral agents</term><term>Arabinoside</term><term>Arabinoslde</term><term>Arabmoslde</term><term>Ascorbic acid</term><term>Beneficial effects</term><term>Beneficial role</term><term>Best results</term><term>Biomedical press</term><term>Brain tissue</term><term>Carrier rate</term><term>Chmcal study</term><term>Chnical</term><term>Clinical efficacy</term><term>Clinical studies</term><term>Collaborative study</term><term>Conclusive evidence</term><term>Core antigen</term><term>Corneal ulceration</term><term>Cytosine arabinoslde</term><term>Dane particles</term><term>Definitive study</term><term>Dos</term><term>Dosage</term><term>Drug therapy</term><term>Early promise</term><term>Echo viruses</term><term>Efficacy</term><term>Encephalitis</term><term>Etiological agent</term><term>Exciting results</term><term>Exogenous interferon</term><term>Genital herpes</term><term>Government authorities</term><term>Hepatitis</term><term>Herpes</term><term>Herpes encephalitis</term><term>Herpes genitalis</term><term>Herpes labialis</term><term>Herpes simplex</term><term>Herpes simplex virus</term><term>Herpes simplex virus type</term><term>Herpes viruses</term><term>Herpes zoster</term><term>High risk</term><term>Historic controls</term><term>Infection</term><term>Influenza</term><term>Influenza epidemics</term><term>Influenza pneumonia</term><term>Influenza viruses</term><term>Interferon</term><term>Lassa fever</term><term>Liver biopsy</term><term>Major problem</term><term>Monophosphate</term><term>Mortahty rate</term><term>Mortality rate</term><term>Neonatal herpes</term><term>Ocular herpes</term><term>Ointment</term><term>Older patients</term><term>Open studies</term><term>Ophthalmic ointment</term><term>Ophthalmic solution</term><term>Other agents</term><term>Other drugs</term><term>Other studies</term><term>Partial reduction</term><term>Personal communication</term><term>Petrolatum base</term><term>Placebo</term><term>Placebo group</term><term>Placebo groups</term><term>Pregnant women</term><term>Primary refection</term><term>Prophylaxis</term><term>Rapid clearance</term><term>Raven press</term><term>Recurrence</term><term>Recurrence rate</term><term>Refection</term><term>Renal function</term><term>Respiratory disease</term><term>Rhinovirus</term><term>Rhinovirus infections</term><term>Rhinovirus type</term><term>Rimantadine</term><term>Several agents</term><term>Shortest time</term><term>Side effects</term><term>Simplex</term><term>Such agents</term><term>Surface antigen</term><term>Therapeutic effect</term><term>Therapeutic efficacy</term><term>Topical treatment</term><term>Toxic level</term><term>Toxicity</term><term>Vaccine</term><term>Viral</term><term>Viral diseases</term><term>Viral infections</term><term>Virus</term><term>Zoster</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>herpes</json:string><json:string>interferon</json:string><json:string>adenine</json:string><json:string>viral</json:string><json:string>antiviral</json:string><json:string>amantadine</json:string><json:string>refection</json:string><json:string>placebo</json:string><json:string>monophosphate</json:string><json:string>zoster</json:string><json:string>toxicity</json:string><json:string>antivlral</json:string><json:string>side effects</json:string><json:string>influenza</json:string><json:string>arabmoslde</json:string><json:string>arabinoslde</json:string><json:string>rhinovirus</json:string><json:string>prophylaxis</json:string><json:string>rimantadine</json:string><json:string>viral diseases</json:string><json:string>chnical</json:string><json:string>arabinoside</json:string><json:string>simplex</json:string><json:string>surface antigen</json:string><json:string>topical treatment</json:string><json:string>encephalitis</json:string><json:string>clinical studies</json:string><json:string>exogenous interferon</json:string><json:string>therapeutic efficacy</json:string><json:string>herpes viruses</json:string><json:string>clinical efficacy</json:string><json:string>vaccine</json:string><json:string>dos</json:string><json:string>ophthalmic solution</json:string><json:string>herpes encephalitis</json:string><json:string>drug therapy</json:string><json:string>open studies</json:string><json:string>recurrence</json:string><json:string>hepatitis</json:string><json:string>pregnant women</json:string><json:string>conclusive evidence</json:string><json:string>neonatal herpes</json:string><json:string>respiratory disease</json:string><json:string>such agents</json:string><json:string>herpes zoster</json:string><json:string>other studies</json:string><json:string>viral infections</json:string><json:string>several agents</json:string><json:string>rhinovirus type</json:string><json:string>antivlral agents</json:string><json:string>ascorbic acid</json:string><json:string>herpes simplex</json:string><json:string>adenine arabinoside monophosphate</json:string><json:string>placebo group</json:string><json:string>raven press</json:string><json:string>antiviral drugs</json:string><json:string>other drugs</json:string><json:string>dane particles</json:string><json:string>adenine arabmoslde</json:string><json:string>adenine arabmoside</json:string><json:string>efficacy</json:string><json:string>infection</json:string><json:string>dosage</json:string><json:string>renal function</json:string><json:string>beneficial effects</json:string><json:string>recurrence rate</json:string><json:string>rapid clearance</json:string><json:string>rhinovirus infections</json:string><json:string>echo viruses</json:string><json:string>adenine arabinoslde</json:string><json:string>other agents</json:string><json:string>antlvlral agents</json:string><json:string>ophthalmic ointment</json:string><json:string>petrolatum base</json:string><json:string>herpes simplex virus</json:string><json:string>best results</json:string><json:string>definitive study</json:string><json:string>placebo groups</json:string><json:string>adenine arabmoslde monophosphate</json:string><json:string>ocular herpes</json:string><json:string>collaborative study</json:string><json:string>corneal ulceration</json:string><json:string>toxic level</json:string><json:string>mortahty rate</json:string><json:string>brain tissue</json:string><json:string>influenza pneumonia</json:string><json:string>mortality rate</json:string><json:string>cytosine arabinoslde</json:string><json:string>older patients</json:string><json:string>adenine arabinoslde monophosphate</json:string><json:string>major problem</json:string><json:string>adenine arabinoside</json:string><json:string>antiviral agent</json:string><json:string>herpes simplex virus type</json:string><json:string>herpes genitalis</json:string><json:string>high risk</json:string><json:string>herpes labialis</json:string><json:string>abrupt onset</json:string><json:string>genital herpes</json:string><json:string>influenza epidemics</json:string><json:string>influenza viruses</json:string><json:string>government authorities</json:string><json:string>etiological agent</json:string><json:string>carrier rate</json:string><json:string>therapeutic effect</json:string><json:string>liver biopsy</json:string><json:string>core antigen</json:string><json:string>partial reduction</json:string><json:string>personal communication</json:string><json:string>early promise</json:string><json:string>beneficial role</json:string><json:string>antiviral agents</json:string><json:string>primary refection</json:string><json:string>exciting results</json:string><json:string>lassa fever</json:string><json:string>shortest time</json:string><json:string>chmcal study</json:string><json:string>historic controls</json:string><json:string>biomedical press</json:string><json:string>ointment</json:string><json:string>virus</json:string></teeft></keywords><author><json:item><name>George J. Galasso</name><affiliations><json:string>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>antiviral agents</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>infectious diseases</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>indications</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dosage and administration of antiviral agents</value></json:item></subject><arkIstex>ark:/67375/6H6-5WX34SM5-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>1</abstractWordCount><abstractCharCount>0</abstractCharCount><keywordCount>4</keywordCount><score>7.012</score><pdfWordCount>9803</pdfWordCount><pdfCharCount>57681</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>24</pdfPageCount><pdfPageSize>468 x 684 pts</pdfPageSize></qualityIndicators><title>An assessment of antiviral drugs for the management of infectious diseases in humans</title><pmid><json:string>6175275</json:string></pmid><pii><json:string>0166-3542(81)90035-8</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Antiviral Research</title><language><json:string>unknown</json:string></language><publicationDate>1981</publicationDate><issn><json:string>0166-3542</json:string></issn><pii><json:string>S0166-3542(00)X0098-8</json:string></pii><volume>1</volume><issue>2</issue><pages><first>73</first><last>96</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1524</json:string><json:string>1976</json:string><json:string>1966</json:string><json:string>1962</json:string><json:string>1978</json:string><json:string>1980</json:string></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>A. Ara</json:string><json:string>Status</json:string><json:string>VlVOstudies</json:string><json:string>Haddad</json:string><json:string>Risk</json:string><json:string>Richard Whltley</json:string><json:string>C. Trepo</json:string><json:string>H. Thomas</json:string></persName><placeName><json:string>Stanford</json:string><json:string>Europe</json:string><json:string>France</json:string><json:string>Weimar</json:string><json:string>Sweden</json:string><json:string>England</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>McAullffe et al</json:string><json:string>Pachuta et al. [32]</json:string><json:string>[50]</json:string><json:string>[1, 26, 40]</json:string><json:string>[4]</json:string><json:string>Merlgan et al. [27]</json:string><json:string>[ 18]</json:string><json:string>[56]</json:string><json:string>Weimar et al. [52]</json:string><json:string>[23, 24]</json:string><json:string>[6]</json:string><json:string>Feldman et al. [11]</json:string><json:string>[33]</json:string><json:string>Mengan et al. [29]</json:string><json:string>[2, 45]</json:string><json:string>[8]</json:string><json:string>[39]</json:string><json:string>[10,21]</json:string><json:string>[1]</json:string><json:string>[54]</json:string><json:string>[31 ]</json:string><json:string>[38]</json:string><json:string>[3]</json:string><json:string>January 1977</json:string><json:string>[1 ]</json:string><json:string>[42]</json:string><json:string>[5]</json:string><json:string>[15]</json:string><json:string>[41]</json:string><json:string>[7]</json:string><json:string>Pazin et al. [36]</json:string><json:string>[14]</json:string><json:string>[9]</json:string><json:string>[51]</json:string><json:string>[16, 17]</json:string><json:string>[35]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-5WX34SM5-3</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - virology</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string></scopus></categories><publicationDate>1981</publicationDate><copyrightDate>1980</copyrightDate><doi><json:string>10.1016/0166-3542(81)90035-8</json:string></doi><id>5B16ABB788D66804F28AADB9F02251C61DB44691</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">An assessment of antiviral drugs for the management of infectious diseases in humans</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1980</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">An assessment of antiviral drugs for the management of infectious diseases in humans</title><author xml:id="author-0000"><persName><forename type="first">George J.</forename><surname>Galasso</surname></persName><affiliation>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205, U.S.A.</affiliation></author><idno type="istex">5B16ABB788D66804F28AADB9F02251C61DB44691</idno><idno type="ark">ark:/67375/6H6-5WX34SM5-3</idno><idno type="DOI">10.1016/0166-3542(81)90035-8</idno><idno type="PII">0166-3542(81)90035-8</idno></analytic><monogr><title level="j">Antiviral Research</title><title level="j" type="abbrev">AVR</title><idno type="pISSN">0166-3542</idno><idno type="PII">S0166-3542(00)X0098-8</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1981"></date><biblScope unit="volume">1</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="73">73</biblScope><biblScope unit="page" to="96">96</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1980</date></creation><langUsage><language ident="en">en</language></langUsage><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>antiviral agents</term></item><item><term>infectious diseases</term></item><item><term>indications</term></item><item><term>dosage and administration of antiviral agents</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1981">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>AVR</jid><aid>81900358</aid><ce:pii>0166-3542(81)90035-8</ce:pii><ce:doi>10.1016/0166-3542(81)90035-8</ce:doi><ce:copyright type="unknown" year="1980"></ce:copyright></item-info><head><ce:title>An assessment of antiviral drugs for the management of infectious diseases in humans</ce:title><ce:author-group><ce:author><ce:given-name>George J.</ce:given-name><ce:surname>Galasso</ce:surname></ce:author><ce:affiliation><ce:textfn>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205, U.S.A.</ce:textfn></ce:affiliation></ce:author-group><ce:date-received day="1" month="12" year="1980"></ce:date-received><ce:date-accepted day="23" month="12" year="1980"></ce:date-accepted><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>antiviral agents</ce:text></ce:keyword><ce:keyword><ce:text>infectious diseases</ce:text></ce:keyword><ce:keyword><ce:text>indications</ce:text></ce:keyword><ce:keyword><ce:text>dosage and administration of antiviral agents</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>An assessment of antiviral drugs for the management of infectious diseases in humans</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>An assessment of antiviral drugs for the management of infectious diseases in humans</title></titleInfo><name type="personal"><namePart type="given">George J.</namePart><namePart type="family">Galasso</namePart><affiliation>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1981</dateIssued><copyrightDate encoding="w3cdtf">1980</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><subject><genre>Keywords</genre><topic>antiviral agents</topic><topic>infectious diseases</topic><topic>indications</topic><topic>dosage and administration of antiviral agents</topic></subject><relatedItem type="host"><titleInfo><title>Antiviral Research</title></titleInfo><titleInfo type="abbreviated"><title>AVR</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1981</dateIssued></originInfo><identifier type="ISSN">0166-3542</identifier><identifier type="PII">S0166-3542(00)X0098-8</identifier><part><date>1981</date><detail type="volume"><number>1</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue-pages"><start>71</start><end>140</end></extent><extent unit="pages"><start>73</start><end>96</end></extent></part></relatedItem><identifier type="istex">5B16ABB788D66804F28AADB9F02251C61DB44691</identifier><identifier type="ark">ark:/67375/6H6-5WX34SM5-3</identifier><identifier type="DOI">10.1016/0166-3542(81)90035-8</identifier><identifier type="PII">0166-3542(81)90035-8</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001402 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001402 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5B16ABB788D66804F28AADB9F02251C61DB44691
|texte= An assessment of antiviral drugs for the management of infectious diseases in humans
}}
| This area was generated with Dilib version V0.6.33. |  |